Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1041]

Low dose exemestane usage in breast cancer

Dr Davide Serrano - European Institute of Oncology, Milan, Italy

Low dose exemestane usage in breast cancer ( Dr Davide Serrano - European Institute of Oncology, Milan, Italy )

BRCA1 and BRCA2 genes and hereditary breast cancers

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

BRCA1 and BRCA2 genes and hereditary breast cancers ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

The Umberto Veronesi Milan Breast Cancer Conference

Dr Paolo Veronesi - European Institute of Oncology, Milan, Italy

The Umberto Veronesi Milan Breast Cancer Conference ( Dr Paolo Veronesi - European Institute of Oncology, Milan, Italy )

4 years of RESONATE data for CLL patients treated with ibrutinib

Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona...

4 years of RESONATE data for CLL patients treated with ibrutinib ( Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Hemcare - multiple myeloma learning programme

Erik Aerts - President of HNHCP, Winterthur, Switzerland

Hemcare - multiple myeloma learning programme ( Erik Aerts - President of HNHCP, Winterthur, Switzerland )

Enasidenib in mIDH relapsed and refractory AML

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

$Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )$

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany

Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )

The role of patient advocates in trial design, participation

Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy

The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid...

Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL

Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL ( Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA )

Gastrectomy and oral drug prescription

Prof Alain Astier – Universidad de Paris, Paris, France

Gastrectomy and oral drug prescription ( Prof Alain Astier – Universidad de Paris, Paris, France )

Improving care for cancer patients

Dr David Hui - MD Anderson Cancer Center, Houston, USA

Improving care for cancer patients ( Dr David Hui - MD Anderson Cancer Center, Houston, USA )

More from ecancer